Zinc Acetate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Zinc Acetate
- Zinc Acetate: From an Undocumented Original Indication to Severe Nonproliferative Diabetic Retinopathy
Zinc Acetate: From an Undocumented Original Indication to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Zinc acetate (DrugBank DB14487) has no approved indication or mechanism-of-action data recorded in this evidence pack, and it is not currently registered with SAHPRA. The TxGNN model’s top prediction is Severe Nonproliferative Diabetic Retinopathy, but this candidate is currently supported by 0 clinical trials and 0 publications — the prediction score is high, but the evidence base is empty.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in evidence pack — zinc acetate has no recorded licences or approved-indication text |
| Predicted New Indication | Severe Nonproliferative Diabetic Retinopathy |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available for zinc acetate in this evidence pack (flagged as data gap DG002, High severity). Based on the model’s own rationale, zinc acts as a cofactor for antioxidant enzymes such as superoxide dismutase (SOD), and the proposed link to diabetic retinopathy rests on a theoretical “oxidative stress mitigation” hypothesis rather than an established pharmacological pathway.
No original indication is recorded for this drug in the evidence pack, so a direct comparison between the original and predicted indications cannot be made here.
Mechanistically, the plausibility is weak: there is no established direct connection between zinc and the VEGF/neovascularization pathway that drives diabetic retinopathy progression, and the model’s rationale explicitly notes this gap. This is consistent with the L5 evidence tier — a high embedding-similarity score with no corroborating clinical or literature support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Zinc acetate is not registered with SAHPRA (market status: Not Marketed; 0 licences on file). No local product, dosage form, or approved-indication information is available for review.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: retrieval of TFDA/PI warnings and contraindications is listed as a Blocking data gap (DG001) in this evidence pack — this must be resolved before any safety pre-assessment (S1) can proceed for this drug.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (severe nonproliferative diabetic retinopathy) has a high TxGNN similarity score but zero supporting clinical trials or literature, and no established mechanistic pathway (L5, model-prediction only). There is insufficient evidence to advance this indication beyond hypothesis generation.
To proceed, the following is needed:
- Mechanism-of-action data for zinc acetate (DG002)
- SAHPRA Professional Information / warnings and contraindications (DG001, Blocking — currently prevents any safety pre-assessment)
- Preclinical or clinical evidence specifically linking zinc supplementation to diabetic retinopathy outcomes (e.g., VEGF pathway or oxidative-stress endpoints)
- Confirmation of any prior/foreign regulatory indication for zinc acetate, since none is on file
Other candidates worth monitoring: two lower-ranked predictions have marginally stronger (though still weak) support and are already flagged as “Research Question” (L4/S1) rather than Hold — bronchitis (rank 2, one indirect common-cold lozenge trial, NCT03309995) and urinary tract infection (rank 10, one sickle-cell zinc-supplementation cohort study, PMID 10398312). Neither is disease-specific evidence, but both may warrant separate, dedicated evaluation ahead of the diabetic retinopathy candidate.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.